Case Report: Rifampicin-Induced Thrombocytopenia in a Patient with Borderline Lepromatous Leprosy

Am J Trop Med Hyg. 2020 Oct;103(4):1441-1442. doi: 10.4269/ajtmh.20-0211.

Abstract

Rifampicin is a highly effective antibacterial drug and an important component of multidrug therapy used to treat leprosy. Side effects of rifampicin are rare with the once-a-month dosage regimen of anti-leprosy multidrug therapy. Here, we report a case of rifampicin-induced thrombocytopenia during anti-leprosy treatment. Although rare, this potential side effect merits attention.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Leprostatic Agents / therapeutic use
  • Leprosy, Borderline / drug therapy*
  • Male
  • Rifampin / adverse effects*
  • Rifampin / therapeutic use
  • Thrombocytopenia / etiology*

Substances

  • Anti-Bacterial Agents
  • Leprostatic Agents
  • Rifampin